Imagion Biosystems Limited (IBXXF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.37 Million AUD | 58.06% |
| 2022 | 5.29 Million AUD | 554.19% |
| 2021 | 809.87 Thousand AUD | -32.8% |
| 2020 | 1.2 Million AUD | -36.52% |
| 2019 | 1.89 Million AUD | 44.02% |
| 2018 | 1.31 Million AUD | 91.39% |
| 2017 | 688.77 Thousand AUD | 52.39% |
| 2016 | 451.99 Thousand AUD | -95.32% |
| 2015 | 9.65 Million AUD | 123.93% |
| 2014 | 4.31 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 8.37 Million AUD | 58.06% |
| 2023 Q3 | 8.37 Million AUD | 15.62% |
| 2023 Q4 | 8.37 Million AUD | 0.0% |
| 2023 Q1 | 7.24 Million AUD | 36.71% |
| 2023 Q2 | 7.24 Million AUD | 0.0% |
| 2022 Q2 | 6.11 Million AUD | 0.0% |
| 2022 Q4 | 5.29 Million AUD | 0.0% |
| 2022 FY | 5.29 Million AUD | 554.19% |
| 2022 Q1 | 6.11 Million AUD | 655.48% |
| 2022 Q3 | 5.29 Million AUD | -13.41% |
| 2021 Q1 | 1.11 Million AUD | -7.33% |
| 2021 FY | 809.87 Thousand AUD | -32.8% |
| 2021 Q4 | 809.87 Thousand AUD | 0.0% |
| 2021 Q3 | 809.87 Thousand AUD | -27.48% |
| 2021 Q2 | 1.11 Million AUD | 0.0% |
| 2020 FY | 1.2 Million AUD | -36.52% |
| 2020 Q1 | 2.19 Million AUD | 15.59% |
| 2020 Q2 | 2.19 Million AUD | 0.0% |
| 2020 Q4 | 1.2 Million AUD | 0.0% |
| 2020 Q3 | 1.2 Million AUD | -45.09% |
| 2019 Q1 | 1.15 Million AUD | -12.64% |
| 2019 Q3 | 1.89 Million AUD | 64.87% |
| 2019 Q4 | 1.89 Million AUD | 0.0% |
| 2019 FY | 1.89 Million AUD | 44.02% |
| 2019 Q2 | 1.15 Million AUD | 0.0% |
| 2018 Q4 | 1.31 Million AUD | 0.0% |
| 2018 Q2 | 1.01 Million AUD | 0.0% |
| 2018 Q1 | 1.01 Million AUD | 47.94% |
| 2018 FY | 1.31 Million AUD | 91.39% |
| 2018 Q3 | 1.31 Million AUD | 29.37% |
| 2017 Q2 | 2.74 Million AUD | 0.0% |
| 2017 Q1 | 2.74 Million AUD | 0.0% |
| 2017 FY | 688.77 Thousand AUD | 52.39% |
| 2017 Q4 | 688.77 Thousand AUD | 0.0% |
| 2017 Q3 | 688.77 Thousand AUD | -74.9% |
| 2016 FY | 451.99 Thousand AUD | -95.32% |
| 2015 FY | 9.65 Million AUD | 123.93% |
| 2014 FY | 4.31 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -132.104% |
| Arrayit Corporation | 7.49 Million USD | -11.708% |
| Atlantic International Corp. | 3.82 Million USD | -118.73% |
| Biocept, Inc. | 22.01 Million USD | 61.957% |
| Bioqual, Inc. | 18.93 Million USD | 55.78% |
| CardioGenics Holdings Inc | 1.79 Million USD | -366.556% |
| DermTech, Inc. | 64.75 Million USD | 87.068% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 98.861% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 32.389% |
| iMD Companies, Inc. | 1.67 Million USD | -400.193% |
| IDenta Corp. | 1.01 Million USD | -726.556% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 70.258% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -2710.674% |
| InVitro International | 78.99 Thousand USD | -10501.746% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 57.553% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -6376.808% |
| Medical Imaging Corp. | 9.51 Million USD | 12.008% |
| NovelStem International Corp. | 4.2 Million USD | -99.1% |
| Optigenex Inc. | 9.57 Million USD | 12.5% |
| PharmChem, Inc. | 558.64 Thousand USD | -1399.036% |
| Proteome Sciences plc | 18.48 Million USD | 54.707% |
| Response Genetics, Inc | 15.86 Million USD | 47.222% |
| Rennova Health, Inc. | 49.66 Million USD | 83.139% |
| RushNet, Inc. | 6.23 Million USD | -34.226% |
| ScreenPro Security Inc. | 1.6 Million USD | -423.203% |
| Stella Diagnostics Inc. | 18 Million USD | 53.49% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -2.076% |
| Todos Medical Ltd. | 50.15 Million USD | 83.304% |